Get the Stockscreener App
31.23
2.33%
0.705
Catalyst Pharmaceuticals Inc stock is traded at $31.23, with a volume of 8.96M.
It is up +2.33% in the last 24 hours and up +24.97% over the past month.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$30.52
Open:
$31.13
24h Volume:
8.96M
Relative Volume:
5.65
Market Cap:
$3.82B
Revenue:
$588.99M
Net Income/Loss:
$214.33M
P/E Ratio:
18.54
EPS:
1.6844
Net Cash Flow:
$208.61M
1W Performance:
+11.02%
1M Performance:
+24.97%
6M Performance:
+46.01%
1Y Performance:
+33.12%
1-Day Range:
$31.08
$31.29
1-Week Range:
$28.14
$31.29
52-Week Range:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.23 | 3.73B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
426.22 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
713.64 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.28 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.08 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.39 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - The AI Journal
Angelini’s $4.1bn Catalyst Deal Opens Door To US Rare Disease Market - Citeline News & Insights
Angelina Pharma To Buy Catalyst For $4.1B; Catalyst Also Settles FIRDAPSE Patent Litigation - RTTNews
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 - GlobeNewswire
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease - Benzinga
Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1B - MSN
Catalyst Pharmaceuticals Agrees to Be Acquired by Angelini Pharma for $4.1 Billion - marketscreener.com
Catalyst Pharmaceuticals and Hetero Labs Ltd. Settle FIRDAPSE Patent Litigation; Hetero to Market Generic Version Starting January 2035 - Quiver Quantitative
Generic FIRDAPSE delayed until Jan. 2035 as Catalyst ends last patent case - Stock Titan
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. - Yahoo! Finance Canada
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com
La italiana Angelini Pharma comprará Catalyst Pharmaceuticals por 4.100 millones de dólares - TradingView
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals announces $200M share repurchase program through 2026 - MSN
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards? - TradingView
Italy’s Angelini said to explore Catalyst Pharma acquisition - MSN
Hussman Strategic Advisors Inc. Sells 42,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Executive Compensation, Stock Awards, and Option Grants 2025 Overview - Minichart
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma - MSN
(CPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Executive pay, ownership and governance detailed in Catalyst (NASDAQ: CPRX) 2025 10-K/A - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Has $3.91 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived - Pharmaceutical Executive
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - TradingView
Catalyst posts Q1 results after the bell May 11; call set for 8:30 ET - Stock Titan
Angelini Pharma Considers Acquisition of Catalyst Pharmaceuticals (CPRX) - GuruFocus
BofA reiterates Catalyst Pharmaceuticals stock rating on M&A report By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals Jumps 6.8% Amid Sector-Wide Rally - AlphaStreet
Catalyst Pharmaceuticals (CPRX) Shares Surge on Acquisition Inte - GuruFocus
Catalyst Pharmaceuticals jumps on report of potential acquisition interest - Quiver Quantitative
Italy’s Angelini Said to Explore Catalyst Pharma Acquisition - Bloomberg.com
Italy's Angelini said to explore acquisition of Catalyst PharmaBloomberg News - marketscreener.com
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma (CPRX:NASDAQ) - Seeking Alpha
Catalyst Pharmaceuticals stock surges on takeover report By Investing.com - Investing.com Canada
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Italy’s Angelini Said to Explore Acquisition of Catalyst Pharma - Bloomberg.com
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution - Sahm
Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors? - Sahm
How Rare-Disease Drug Momentum At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - TradingView
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):